Lobe Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LOBEF research report →
Price Chart
About the company
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder.
- CEO
- Frederick Dominick Sancilio
- IPO
- 2023
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on LOBEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $11.06M
- P/E
- -2.43
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 7.36
- EV/EBITDA
- -2.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -338.76%
- ROIC
- -193.66%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-4,176,322
- Net Income
- $-4,424,660-0.1%
- EPS
- $-0.03+11.9%
- OCF Growth
- -116.3%
- FCF Growth
- -116.3%
- 52W High
- $0.11
- 52W Low
- $0.00
- 50D MA
- $0.04
- 200D MA
- $0.02
- Beta
- 0.29
- RSI (14)
- 52
- Avg Volume
- 76.71K
No earnings-call transcripts are available for LOBEF yet.
- Free Float
- 27.0%
- Shares Outstanding
- 308.18M
- Float Shares
- 83.08M
Our LOBEF coverage
Recent articles, reports, and earnings notes.
No research on LOBEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LOBEF report →Lobe Sciences Appoints Tracy L. Goeken, M.D.
accessnewswire.com · Oct 20
Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors
accessnewswire.com · Oct 14
Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth
accessnewswire.com · Oct 8
Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit
accessnewswire.com · Sep 14
Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
newsfilecorp.com · Sep 14
Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
accessnewswire.com · Aug 31
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
accessnewswire.com · Aug 28
Lobe Sciences Expands Leadership Team with New CFO Appointment
accessnewswire.com · Aug 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.